Biologics in Dermatology: What They Target and Who Qualifies
Biologics are not a newer, stronger version of a steroid cream. They are a different category of medicine entirely, proteins engineered to block one specific part of the immune response rather than turning the volume down on immunity across the board. That distinction matters for anyone trying to understand why their dermatologist has or hasn't mentioned them.
What Biologics Actually Do
Conventional treatments for inflammatory skin conditions work broadly. Methotrexate, cyclosporine, and corticosteroids reduce immune activity systemically, which is why they come with a long list of monitoring requirements. Biologics work differently. They are large-molecule proteins, most are monoclonal antibodies, designed to bind to one specific target: a cytokine, a cytokine receptor, or a cell-surface protein involved in the inflammatory pathway driving the condition.
In psoriasis, the main targets are interleukin-17 (IL-17), interleukin-23 (IL-23), and tumour necrosis factor-alpha (TNF-alpha). Each of these cytokines plays a distinct role in the inflammatory cascade that causes the rapid skin-cell turnover and plaque formation characteristic of moderate-to-severe plaque psoriasis. Drugs targeting IL-23, for example, block a signal that activates the Th17 immune pathway; without that signal, the downstream inflammation that reaches the skin is significantly reduced. In atopic dermatitis, IL-4 and IL-13 are the primary targets, reflecting a different immune axis, the Th2 pathway, that drives the skin barrier dysfunction and itch cycle in that condition.
The specificity is the point. Because the drug binds to one target rather than suppressing immunity broadly, the side-effect profile is different from conventional immunosuppressants, though not absent.
Which Conditions Are Treated with Biologics
In dermatology, biologics currently have the most established use in three areas: moderate-to-severe plaque psoriasis, atopic dermatitis (eczema) that has not responded adequately to topical and conventional systemic treatments, and hidradenitis suppurativa. Chronic spontaneous urticaria that does not respond to antihistamines is managed with omalizumab, which targets IgE rather than a cytokine. Alopecia areata has more recently seen biologic options enter clinical use, targeting the JAK-STAT pathway, though JAK inhibitors are technically small molecules rather than biologics, the distinction is often blurred in patient conversations.
The common thread is that these are conditions where the underlying immune driver is well-characterised enough that a specific target can be identified and blocked. Conditions with more complex or less understood immune mechanisms are less likely to have an approved biologic option.
Who Qualifies, and the Criteria Behind That Decision
Qualifying for a biologic is not simply about how bad the skin looks. Dermatologists use validated scoring tools, PASI (Psoriasis Area and Severity Index) for psoriasis, EASI (Eczema Area and Severity Index) for atopic dermatitis, to establish objective severity. A patient with moderate-to-severe disease by these scores who has not responded adequately to at least one conventional systemic treatment, or who cannot tolerate conventional treatments due to organ toxicity or contraindications, is typically in the range where biologics are considered.
Beyond severity and treatment history, several factors are assessed before starting a biologic. Active infections, including tuberculosis, must be screened for and ruled out, because blocking certain immune pathways can reactivate latent infections. Hepatitis B status is checked. A history of certain malignancies may affect which biologic is appropriate. Patients with inflammatory bowel disease who have psoriasis, for example, need a biologic that does not worsen intestinal inflammation, some TNF-alpha inhibitors are used in IBD, while IL-17 inhibitors are generally avoided in that population.
Cost and access are a real part of the picture in India. Biologics are significantly more expensive than conventional systemic treatments, and not all are available under government health schemes or insurance panels. This is a practical constraint that a dermatologist managing these cases will factor into the conversation.
What Biologics Cannot Fix
Biologics manage disease; they do not cure it. For most patients with psoriasis or atopic dermatitis, stopping the biologic means the condition returns. They also do not work for everyone, primary non-response, where the drug simply does not produce adequate improvement, occurs in a proportion of patients, and secondary non-response, where efficacy wanes over time, is also documented. Some patients develop antibodies against the biologic itself, which reduces its effectiveness.
They are not appropriate for mild disease, for conditions where the immune target is not well defined, or for patients whose skin condition has not been formally diagnosed and typed. Self-treating or seeking a biologic without a confirmed diagnosis and specialist oversight is not a path that exists in practice, these are prescription-only, administered by injection or infusion, and require ongoing monitoring. A dermatologist managing a patient on a biologic will schedule regular assessments to track response, watch for adverse effects, and decide whether the current agent remains the right choice.
The range of biologics available, their targets, and the evidence behind them continues to develop. What qualifies a patient today reflects current guidelines, available agents, and local access, all of which a specialist is best placed to assess for an individual case.
Discover expert advice and the latest updates in Skin Care, Hair Care, Wellness, Dermatology, and more at Stay Young guide to lasting beauty and holistic health!
